Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune

The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.

Cullinan Oncology, Inc. is changing course and increasing its focus on inflammation and immunology. The company will rebrand as Cullinan Therapeutics, Inc. as it moves CLN-978, its CD19xCD3-directed bispecific antibody, from B-cell non-Hodgkin lymphoma (B-NHL) to autoimmune diseases, starting with systemic lupus erythematosus (SLE).

Cambridge, MA-based Cullinan is just the latest of several oncology-focused companies to expand into rheumatology – particularly as the space...